BeiGene
BGNE
#881
Rank
NZ$35.84 B
Marketcap
$326.49
Share price
1.71%
Change (1 day)
0.44%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : NZ$9.23 B

According to BeiGene 's latest financial reports the company's total assets are NZ$9.23 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31NZ$9.17 B-8.64%
2022-12-31NZ$10.04 B-19.38%
2021-12-31NZ$12.46 B60.05%
2020-12-31NZ$7.78 B225.82%
2019-12-31NZ$2.39 B-28.7%
2018-12-31NZ$3.35 B127.51%
2017-12-31NZ$1.47 B151.51%
2016-12-31NZ$0.58 B243.01%
2015-12-31NZ$0.17 B149.87%
2014-12-31NZ$68.35 M375.82%
2013-12-31NZ$14.36 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
NZ$29.37 M-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$3.20 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA